Litigation Details for Regeneron Pharmaceuticals, Inc. v. Amgen Inc. (D. Del. 2022)
✉ Email this page to a colleague
Regeneron Pharmaceuticals, Inc. v. Amgen Inc. (D. Del. 2022)
| Docket | ⤷ Try a Trial | Date Filed | 2022-05-27 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 15:1 Antitrust Litigation | Assigned To | Jennifer L. Hall |
| Jury Demand | Plaintiff | Referred To | Jennifer L. Hall |
| Patents | 8,030,457; 8,563,698; 8,829,165; 8,859,741; 8,871,914; 8,883,983; 8,889,834 | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in Regeneron Pharmaceuticals, Inc. v. Amgen Inc.
The biologic drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Regeneron Pharmaceuticals, Inc. v. Amgen Inc. (D. Del. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-05-27 | 1 | Complaint | market as a result of Amgen’s patent litigation campaign. Amgen’s patent challenge to Praluent® was ultimately…has a patent that specifically covers Repatha®. Amgen, 850 F. App’x at 796 (citing U.S. Patent 8,030,… that Amgen’s patents were invalid, thereby stopping Amgen’s campaign to use the patent laws to exclude…Regeneron a patent that covers the precise amino acid sequence of Praluent®. Id.; see U.S. Patent No. 8,062,640…Praluent® infringed two Amgen patents. Critically, the asserted Amgen patents did not specifically disclose | External link to document |
| 2023-08-30 | 129 | Redacted Document | market as a result of Amgen’s patent litigation campaign. Amgen’s patent challenge to Praluent® was…has a patent that specifically covers Repatha®. Amgen, 850 F. App’x at 796 (citing U.S. Patent 8,030,457… that Amgen’s patents were invalid, thereby stopping Amgen’s campaign to use the patent laws to exclude…Regeneron a patent that covers the precise amino acid sequence of Praluent®. Id.; see U.S. Patent No. 8,…Praluent® infringed two Amgen patents. Critically, the asserted Amgen patents did not specifically disclose | External link to document |
| 2023-10-04 | 156 | Redacted Document | U.S. Patent No. 8,030,457 covers Repatha®. Amgen admits that it brought an action for patent infringement….S. Patent and Trademark office issued U.S. Patent No. 8,062,640 in 2011, and that U.S. Patent No.… a declaratory judgment of patent infringement of United States Patent Nos. 8,563,698, 8,829,165, … alleging that Praluent® infringed Amgen’s patents and that it sought an injunction against Regeneron…quote or characterize a brief filed by Amgen in patent litigation in the District of Delaware. That | External link to document |
| 2023-04-04 | 64 | Answer to Complaint | U.S. Patent No. 8,030,457 covers Repatha®. Amgen admits that it brought an action for patent infringement….S. Patent and Trademark office issued U.S. Patent No. 8,062,640 in 2011, and that U.S. Patent No. …for a declaratory judgment of patent infringement of United States Patent Nos. 8,563,698, 8,829,165, …lawsuit alleging that Praluent® infringed Amgen’s patents and that it sought an injunction against Regeneron…quote or characterize a brief filed by Amgen in patent litigation in the District of Delaware. That | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
